The FDA issued draft guidance on Oct. 27 that would let a company add new patient-specific variants to an approved individualized gene-editing product without running new clinical trials, HHS announced.
The same day, the Centers for Medicare and Medicaid Services said it will widen its Cell and Gene Therapy Access Model beyond sickle cell disease. The two steps address the approval of a treatment and who pays for it. The FDA’s change is the larger one, because it moves the unit of approval from a single patient’s therapy to a set of boundaries inside which many patients’ therapies can differ.
How the Individualized Feature Space Works
The draft guidance is titled “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management.” It covers biologics license applications for therapies built to target one patient’s specific genetic variant, according to the HHS announcement.
Its central concept is the Individualized Feature Space, a set of predefined limits within which a product can vary from patient to patient while staying under one license. A new variant that falls inside those limits, backed by assay data showing adequate safety and activity, can be added without new clinical trials.
After approval, sponsors would add variants through a streamlined review that relies on the original clinical trials plus laboratory data on the new variant. The guidance also covers manufacturing, safety testing for unintended genetic changes, and product naming and labeling.
Safety Testing and the Rare Disease Framework
The guidance applies the FDA’s Rare Disease Framework. Kyle Diamantas, the acting commissioner of food and drugs, said in the announcement that “a one size fits all approach to treatment simply does not work.” Karim Mikhail, director of the FDA’s Center for Biologics Evaluation and Research, called the guidance a clear and scientifically rigorous framework for submission and postapproval management.
The flexibility rests on laboratory assays for variants that no patient has yet received. The guidance’s section on testing for unintended genetic changes is where that risk is addressed. The public can comment on Docket FDA-2026-D-11783 at regulations.gov within 30 days of the guidance’s Federal Register publication, and the FDA posted a recorded webinar summary on its YouTube channel.
CMS Expands the Cell and Gene Therapy Access Model
CMS will broaden the voluntary model, which now focuses on sickle cell disease, and invite manufacturers of therapies for other conditions to apply. Under the model, CMS negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid programs.
An initial evaluation found that CMS-led negotiations for sickle cell therapies reduced states’ administrative burden and, by pooling beneficiaries, strengthened their bargaining leverage, the announcement said. Dr. Mehmet Oz, the CMS administrator, said, “A medical breakthrough only matters to patients if they can get it.” CMS will issue a Request for Applications that lets negotiations start sooner after FDA approval or licensure, and it will accept therapies that already have approval. The announcement says that request will come in the coming months.
